canertinib has been researched along with Leukemia, Lymphocytic, T Cell in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gréen, A; Gréen, H; Hallbeck, AL; Holmlund, B; Jönsson, JI; Severinsson, EA; Trinks, C; Walz, TM | 1 |
1 other study(ies) available for canertinib and Leukemia, Lymphocytic, T Cell
Article | Year |
---|---|
The pan-ErbB tyrosine kinase inhibitor canertinib induces caspase-mediated cell death in human T-cell leukemia (Jurkat) cells.
Topics: Apoptosis; Caspases; Humans; Jurkat Cells; Leukemia, T-Cell; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morpholines; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Receptors, Antigen, T-Cell; ZAP-70 Protein-Tyrosine Kinase | 2011 |